Larimar Therapeutics (LRMR) Securities Fraud Investigation

Shamis & Gentile, P.A. is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar Therapeutics" or the "Company") (LRMR). Impacted investors are advised to contact the firm now.

What's Being Investigated?

Attorneys are investigating whether Larimar Therapeutics misrepresented or omitted material information regarding the safety profile of its lead product candidate, nomlabofusp. From approximately December 2024, through September 2025, Larimar Therapeutics and its executives appear to have issued multiple public statements and earnings releases reporting the safety and efficacy of nomlabofusp. These communications described long-term dosing as “generally well tolerated” and cited progress toward regulatory milestones. The investigation is examining whether these statements sufficiently reflected known safety risks or adverse events, including reports of severe allergic reactions, and whether appropriate disclosures were included in the Company’s public filings.

The Market Reaction

On September 29, 2025, before the market opened, Larimar Therapeutics disclosed that 7 of 39 patients in its Friedreich’s ataxia clinical trial had experienced anaphylaxis while receiving nomlabofusp. Following this news, Larimar Therapeutics’s stock fell $1.72 per share, or 33.6%, to close at $3.38.

What Investors Can Do?

If you purchased Larimar Therapeutics (NASDAQ: LRMR) securities between December 2024 and September 2025, you may be eligible to participate in this securities investigation and seek compensation. Contact Shamis & Gentile today to discuss your options.

Shamis & Gentile, P.A. stands out as an advocate for investors who are victims of securities fraud. The firm is committed to securing recoveries for investors who have incurred damages due to false and misleading statements or other corporate misconduct by public companies. Shamis & Gentile has recovered over $1 billion for consumers nationwide. Its extensive experience, expertise and resources enable the firm to resolve disputes in a wide range of matters, including class actions, mass torts and mass arbitrations.

Attorney advertising. Prior results do not guarantee similar outcomes.